Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467736 | 0.85 | PDE10A (0.49) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL305885 | 0.83 | PDE10A (0.53) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL29953235 | 0.83 | PDE10A (0.53) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL9000299 | 0.80 | PDE10A (0.54) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL8561899 | 0.79 | PDE10A (0.49) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL8561898 | 0.79 | PDE10A (0.49) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL1092131 | 0.79 | PDE10A (0.49) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL1092487 | 0.79 | PDE10A (0.49) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL13351976 | 0.79 | PDE10A (0.49) | PDE10APOLBNCOA1NCOA3ALDH1A1 | |
| SCHEMBL1092129 | 0.79 | PDE10A (0.49) | PDE10APOLBNCOA1NCOA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116670144-A | Tricyclic compounds and uses thereof | 南京再明医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-5622966-A | BACTERICIDES TREATING INFECTIONS | WARNER-LAMBERT COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| CN-1138033-A | Process for produducing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1996-12-18 | — | — | CN | disclosed |
| US-5446044-A | Bactericides | WARNER-LAMBERT COMPANY (US) | 1995-08-29 | — | — | US | disclosed |
| US-5384407-A | Pyrrolidine compounds | WARNER-LAMBERT COMPANY (US) | 1995-01-24 | — | — | US | disclosed |
| US-5342844-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1993016077-A1 | 7-SUBSTITUTED QUINOLONES AND NAPHTHYRIDONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |
| US-5221676-A | 7-substituted quinolones and naphthyridones as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1993-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | PDE10A 919/4885POLB 1701/4885NCOA1 2047/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | PDE10A 1436/4885POLB 1502/4885NCOA1 1546/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | PDE10A 919/4885POLB 1701/4885NCOA1 2047/4885 |
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | PDE10A 1237/4885POLB 3154/4885NCOA1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.